EFM
DNTH icon

E Fund Management’s Dianthus Therapeutics DNTH Stock Holding History

E Fund Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497K Buy
5,094
+1,169
+30% +$102K 0.01% 270
2026
Q1 		$329K Buy
+3,925
New +$227K 0.01% 370

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

E Fund Management's DNTH Position: Q2 2026 in Review

E Fund Management increased its Dianthus Therapeutics (DNTH) stake by 30% in Q2 2026, buying an estimated $102K and bringing the position to 5,094 shares worth $497K. The position accounts for 0.01% of the portfolio, ranked #270.

E Fund Management first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • E Fund Management held 5,094 shares of Dianthus Therapeutics worth $497K as of Q2 2026.
  • E Fund Management bought 1,169 Dianthus Therapeutics shares in Q2 2026, an estimated $102K.
  • Dianthus Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #270 holding.
  • E Fund Management first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.